基于miR-28的组合疗法通过重新连接DNA复制来削弱侵略性的B细胞淋巴瘤生长
Teresa Fuertes1, Emigdio Álvarez-Corrales2, Carmen Gómez-Escolar1
1B Cell Biology Laboratory Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Cell death & disease
|October 18, 2023
概括
使用microRNA-28 (miR-28) 和ibrutinib的新型组合疗法在治疗扩散性大B细胞淋巴瘤 (DLBCL) 中表现有前途. 这种方法通过损害DNA复制来增强抗瘤效应,并为患者提供了新的生存预测指标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的B细胞恶性瘤,通常用R-CHOP化疗治疗.
- 许多DLBCL患者在标准R-CHOP治疗后表现出耐药性或复发,需要新的治疗策略.
研究的目的:
- 研究DLBCL中microRNA-28 (miR-28) 的治疗潜力,无论是作为单一疗法还是与ibrutinib结合使用.
- 阐明 miR-28 和 ibrutinib 的联合抗瘤作用的分子机制.
- 确定一个潜在的基因特征来预测ABC-DLBCL中的患者结果.
主要方法:
- 进行了体外和体内研究,以评估miR-28和ibrutinib的疗效.
- 进行了分子分析,以了解对细胞循环停止和DNA复制的影响.
- 基因表达概况被用于识别预测签名.
主要成果:
- 与单一治疗相比,与miR-28和易布鲁替尼的联合治疗显示出潜在的抗瘤活性.
- 组合疗法诱导了一种特定的转录细胞循环停止程序,通过抑制原始激活和分叉进展来损害DNA复制.
- 确定了一种miR-28-plus-ibrutinib基因特征,其下调与ABC-DLBCL患者的生存率改善相关.
结论:
- 结合ibrutinib的miR-28代表了DLBCL的一个有前途的新疗法策略.
- 这种组合疗法在协同作用下损害了DNA复制,从而增强了抗瘤作用.
- miR-28-plus-ibrutinib基因特征作为一种新的生物标志物,用于预测ABC-DLBCL的治疗结果.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.2K
11:44Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
7.7K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:27Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K